Novo Nordisk: Don't Stop Purchasing The Dip

The Value PortfolioInvesting Group LeaderFollow5ShareSavePlay(8min)CommentsSummaryNovo Nordisk remains a compelling investment despite share price weakness, driven by robust innovation and a resilient, diversified drug pipeline.NVO delivered 10% sales growth, $5B FCF, and a 4.8% dividend yield in 2025, comfortably funding both dividends and buybacks.GLP-1 competition is intensifying, but market expansion and strong international growth offset U.S. market share erosion, supporting continued revenue strength.With a single-digit P/E, new rare disease and obesity drugs, and a 7.5% shareholder yield, NVO is positioned for sustainable returns despite patent and competitive risks.The Retirement Forum members get exclusive access to our real-world portfolio. See all our investments here » Carolina Rudah/iStock via Getty Images Novo Nordisk A/S (NVO) is a multinational pharmaceutical company best known for Wegovy and Ozempic, GLP-1 drugs best known for revolutionizing weight loss. Despite that, the company's share price has dropped substantially, with continued weakness since we recommendedThis article was written byThe Value Portfolio37.66K FollowersFollowThe Value Portfolio specializes in building retirement portfolios and utilizes a fact-based research strategy to identify investments. This includes extensive readings of 10Ks, analyst commentary, market reports, and investor presentations. He invests real money in the stocks he recommends. He is the leader of the investing group The Retirement Forum with features including: model portfolios, macro overviews, in-depth company analysis and retirement planning information. Learn more.Analyst’s Disclosure: I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.